Relay Therapeutics (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 1,800 Shares

by · The Markets Daily

Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) CFO Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $15.00, for a total value of $27,000.00. Following the completion of the transaction, the chief financial officer owned 213,867 shares in the company, valued at $3,208,005. This trade represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Thomas Catinazzo also recently made the following trade(s):

  • On Tuesday, April 7th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $13.01, for a total value of $230,498.17.
  • On Wednesday, January 28th, Thomas Catinazzo sold 1,695 shares of Relay Therapeutics stock. The shares were sold at an average price of $8.45, for a total value of $14,322.75.
  • On Tuesday, January 27th, Thomas Catinazzo sold 13,820 shares of Relay Therapeutics stock. The shares were sold at an average price of $7.62, for a total value of $105,308.40.

Relay Therapeutics Trading Up 3.4%

Shares of RLAY stock opened at $15.00 on Friday. The business’s 50 day moving average is $9.95 and its two-hundred day moving average is $8.11. Relay Therapeutics, Inc. has a twelve month low of $2.07 and a twelve month high of $15.00. The company has a market capitalization of $2.68 billion, a P/E ratio of -9.26 and a beta of 1.57.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.06. The business had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $4.34 million. As a group, equities analysts predict that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Relay Therapeutics

A number of institutional investors have recently made changes to their positions in RLAY. Torren Management LLC acquired a new position in shares of Relay Therapeutics in the fourth quarter worth $30,000. Smartleaf Asset Management LLC raised its holdings in shares of Relay Therapeutics by 288.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock worth $37,000 after acquiring an additional 3,287 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Relay Therapeutics in the fourth quarter worth $46,000. Captrust Financial Advisors acquired a new position in shares of Relay Therapeutics in the second quarter worth $49,000. Finally, Cerity Partners LLC acquired a new position in shares of Relay Therapeutics in the second quarter worth $51,000. 96.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Citizens Jmp lifted their price target on Relay Therapeutics from $15.00 to $17.00 and gave the company a “market outperform” rating in a research note on Tuesday, March 17th. Barclays lifted their price objective on Relay Therapeutics from $17.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday. Wells Fargo & Company lifted their price objective on Relay Therapeutics from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, March 17th. HC Wainwright lifted their price objective on Relay Therapeutics from $14.00 to $19.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Relay Therapeutics in a report on Monday, March 16th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.43.

Check Out Our Latest Stock Report on RLAY

Relay Therapeutics Company Profile

(Get Free Report)

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.

See Also